Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Commentary|Articles|June 11, 2026
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
During the
Related to this article
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
Advertisement
Advertisement